Adrenocortical Carcinoma: The Value of Lymphadenectomy.
Adrenocortical carcinoma
Lymph node dissection
Survival
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
09
08
2021
accepted:
18
10
2021
pubmed:
19
11
2021
medline:
8
2
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Adrenocortical carcinoma (ACC) staging does not account for the number of positive nodes. The prognostic value of quantitative metastatic nodal burden is unknown. The National Cancer Database was retrospectively queried from 2004-2016 to identify patients with Stage I-III ACC undergoing adrenalectomy. Patients who underwent lymphadenectomy (LAD) were further studied. Demographics, TNM staging, tumor characteristics, and surgical approach were analyzed. 386 LADs were identified. The median number of nodes examined was 2 (IQR 2-6), with no difference by surgical approach '[laparoscopic, 3 (1-3); robotic, 1.5 (1-4.5); open, 2 (1-7), p = 0.493]. In LADs with cN0 disease, positive nodes were seen in 17.5% of patients; an average of 6 (1-12) nodes were examined in patients who upstaged to pN1 disease compared with an average of 2 (1-6) nodes in those who remained pN0. Median survival was incrementally worse for patients with more positive nodes (62.8 vs. 21.9 vs. 13.7 vs. 11.3 vs. 10.7 months for 0, 1, 2, 3, and ≥ 4 positive nodes, respectively, p < 0.01). On multivariate analysis, significant prognostic factors for poor survival included older age, ≥ 2 comorbidities, pT3, and pT4. The strongest prognostic factor for poor survival was the number of positive nodes (1 node, hazards ratio [HR] 2.3, 95% confidence interval [CI] 1.5-3.6; 2 nodes, HR 1.3, 95% CI 0.6-3.0; 3 nodes, HR 3.0, 95% CI 1.1-8.0; ≥ 4 nodes, HR 4.0, 95% CI 2.5-6.2). Lymphadenectomy was associated with improved survival (HR 0.82, 95% CI 0.67-0.99). Higher quantitative metastatic nodal burden is a robust prognostic factor for worse survival in ACC.
Sections du résumé
BACKGROUND
BACKGROUND
Adrenocortical carcinoma (ACC) staging does not account for the number of positive nodes. The prognostic value of quantitative metastatic nodal burden is unknown.
METHODS
METHODS
The National Cancer Database was retrospectively queried from 2004-2016 to identify patients with Stage I-III ACC undergoing adrenalectomy. Patients who underwent lymphadenectomy (LAD) were further studied. Demographics, TNM staging, tumor characteristics, and surgical approach were analyzed.
RESULTS
RESULTS
386 LADs were identified. The median number of nodes examined was 2 (IQR 2-6), with no difference by surgical approach '[laparoscopic, 3 (1-3); robotic, 1.5 (1-4.5); open, 2 (1-7), p = 0.493]. In LADs with cN0 disease, positive nodes were seen in 17.5% of patients; an average of 6 (1-12) nodes were examined in patients who upstaged to pN1 disease compared with an average of 2 (1-6) nodes in those who remained pN0. Median survival was incrementally worse for patients with more positive nodes (62.8 vs. 21.9 vs. 13.7 vs. 11.3 vs. 10.7 months for 0, 1, 2, 3, and ≥ 4 positive nodes, respectively, p < 0.01). On multivariate analysis, significant prognostic factors for poor survival included older age, ≥ 2 comorbidities, pT3, and pT4. The strongest prognostic factor for poor survival was the number of positive nodes (1 node, hazards ratio [HR] 2.3, 95% confidence interval [CI] 1.5-3.6; 2 nodes, HR 1.3, 95% CI 0.6-3.0; 3 nodes, HR 3.0, 95% CI 1.1-8.0; ≥ 4 nodes, HR 4.0, 95% CI 2.5-6.2). Lymphadenectomy was associated with improved survival (HR 0.82, 95% CI 0.67-0.99).
CONCLUSIONS
CONCLUSIONS
Higher quantitative metastatic nodal burden is a robust prognostic factor for worse survival in ACC.
Identifiants
pubmed: 34792698
doi: 10.1245/s10434-021-11051-5
pii: 10.1245/s10434-021-11051-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1965-1970Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9.
doi: 10.1530/EJE-13-0519
Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–8.
doi: 10.1007/s00268-005-0329-x
Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.
doi: 10.1007/s10434-999-0719-7
Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–7.
doi: 10.1007/s00268-001-0047-y
Tella SH, Kommalapati A, Yaturu S, Kebebew E. Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database. J Clin Endocrinol Metab. 2018;103:3566–73.
doi: 10.1210/jc.2018-00918
Reibetanz J, Rinn B, Kunz AS, Flemming S, Ronchi CL, et al. Patterns of lymph node recurrence in adrenocortical carcinoma: possible implications for primary surgical treatment. Ann Surg Oncol. 2019;26:531–8.
doi: 10.1245/s10434-018-6999-z
Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, et al. Association of quantitative metastatic lymph node burden with survival in hypopharyngeal and laryngeal cancer. JAMA Oncol. 2018;4:985–9.
doi: 10.1001/jamaoncol.2017.3852
Alanee S, Dynda D, Holland B. Prevalence and prognostic value of lymph node dissection in treating adrenocortical carcinoma: a national experience. Anticancer Res. 2015;35:5575–9.
pubmed: 26408728
National Comprehensive Cancer Network Neuroendocrine and Adrenal Tumors (Version 2.2020).
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018;179:G1-46.
doi: 10.1530/EJE-18-0608
Panjwani S, Moore MD, Gray KD, Finnerty BM, Beninato T, et al. The impact of nodal dissection on staging in adrenocortical carcinoma. Ann Surg Oncol. 2017;24:3617–23.
doi: 10.1245/s10434-017-6064-3
Dickson PV, Kim L, Yen TWF, Yang A, Grubbs EG, et al. Evaluation, staging, and surgical management for adrenocortical carcinoma: an update from the SSO endocrine and head and neck disease site working group. Ann Surg Oncol. 2018;25:3460–8.
doi: 10.1245/s10434-018-6749-2
Deschner BW, Stiles ZE, DeLozier OM, Drake JA, Tsao M, et al. Critical analysis of lymph node examination in patients undergoing curative-intent resection for adrenocortical carcinoma. J Surg Oncol. 2020;122:1152–62.
doi: 10.1002/jso.26138
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2. J Natl Comp Cancer Netw. 2018;16:693–702.
doi: 10.6004/jnccn.2018.0056
Amin MB, Edge SB, American Joint Committee on C AJCC cancer staging manual. 2017.
Gerry JM, Tran TB, Postlewait LM, Maithel SK, Prescott JD, et al. Lymphadenectomy for Adrenocortical carcinoma: is there a therapeutic benefit? Ann Surg Oncol. 2016;23:708–13.
doi: 10.1245/s10434-016-5536-1
Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9.
doi: 10.1097/SLA.0b013e3182367ac3
Nilubol N, Patel D, Kebebew E. Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? A population-based study. World J Surg. 2016;40:697–705.
doi: 10.1007/s00268-015-3283-2